New Delhi: After Thrombosis with Thrombocytopenia Syndrome (TTS), it has now been found that British-Swedish pharma giant AstraZeneca’s COVID-19 vaccine, made in collaboration with Oxford University can raise the risk of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) , a rare but fatal blood clotting disorder, claimed researchers. While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine sold as Covishield in India and Vaxzevria in Europe at the height of the COVID pandemic in 2021, IANS reported.
“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.
In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Washington: After the European Space Agency (ESA) discovered liquid water under the southern polar ice…
Mumbai: Sara Ali Khan, known for her bold and flamboyant nature, has often grabbed headlines…
Puri: Three persons including a woman and two boys sustained critical burn injuries in accidental…
Washington: In what is unlikely to be music to New Delhi’s ears, the United States…
As our world rapidly urbanises, cities are becoming home to a new generation of leaders…
Puri: Police have arrested five persons in connection with a double murder in Odisha's Puri…
Mumbai: Come Friday, ‘Singham Again’ and ‘Bhool Bhuliayaa 3’ will be fighting for box-office records.…
Bhubaneswar: Odisha's Deputy Chief Minister Pravati Parida will go on 7-day tour to London on…